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ABSTRACT
Purpose To perform a comprehensive and systematic review regarding ophthalmic adverse drug reactions (ADRs) to systemic drugs to: (i)
systematically summarize existing evidence, (ii) identify areas, ophthalmic ADRs or drugs that lacked systematization or assessment (namely
drugs with original studies characterizing speciﬁc ophthalmic ADRs but without causality assessment nor without meta-analysis).
Methods Systematic review of several electronic databases (last search 1/7/2012): Medline, SCOPUS, ISI web of knowledge, ISI Confer-
ence Proceedings, International Pharmaceutical Abstracts and Google scholar. Search query included: eye, ocular, ophthalmic, ophthalmol-
ogy, adverse and reaction. Inclusion criteria were: (i) Primary purpose was to assess an ophthalmic ADR to a systemic medication; (ii) Patient
evaluation performed by an ophthalmologist; (iii) Studies that speciﬁed diagnostic criteria for an ocular ADR. Different types of studies were
included and analyzed separately. Two independent reviewers assessed eligibility criteria, extracted data and evaluated risk of bias.
Results From 562 studies found, 32 were included (1 systematic review to sildenaﬁl, 11 narrative reviews, 1 trial, 1 prospective study, 6
transversal studies, 6 spontaneous reports and 6 case series). Drugs frequently involved included amiodarone, sildenaﬁl, hydroxychloroquine
and biphosphonates. Frequent ophthalmic ADRs included: keratopathy, dry eye and retinopathy.
Conclusions To increase evidence about ophthalmic ADRs, there is a need for performing speciﬁc systematic reviews, applying strictly the
World Health Organization’s (WHO) deﬁnition of ADR and WHO causality assessment of ADRs.
Some ophthalmic ADRs may be frequent, but require ophthalmological examination; therefore, ophthalmologists’ education and protocols
of collaboration between other specialties whenever they prescribe high-risk drugs are suggestions for the future. Copyright © 2014 John
Wiley & Sons, Ltd.
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INTRODUCTION
Ophthalmology is perhaps one of the medical specialties
in which there are the fewest assessed adverse drug
reactions (ADRs), representing a particular challenge
in Pharmacovigilance.1 However, the eye is a complex
organ in which minimal impairment can produce a sub-
stantial functional effect.2 Ophthalmic ADRs are
usually not continuously detected, although they might
be either frequent or speciﬁc of a drug or drug group,
such as acute angle-closure glaucoma and myopic
shift caused by topiramate,3 cataracts provoked by
corticosteroids,4 ﬂoppy iris syndrome caused by
tamsulosine5 and uveitis caused by rifabutin.6
Some ADRs are rare but can cause irreversible
blindness (such as in optic atrophy provoked by eth-
ambutol),7 while others are extremely frequent but
usually harmful (namely cornea verticillata caused
by amiodarone).8
There are reports that suggest ophthalmic ADRs
provoked by a systemic drug, but remain unsupported
because no systematic review has been performed.
Many ophthalmic ADRs have been identiﬁed solely
due to spontaneous reports, namely blurred vision
caused by leuprolide,9 or other ophthalmic ADRs
caused by different drugs such as biphosphonates,
cetirizine or isotretinoin.2 Therefore, on the one hand,
prospective studies or trials should be performed to
study the causality of each drug to each ophthalmic
ADR; on the other hand, a systematic review should
*Correspondence to: A. Miguel, Department of Health Information and Deci-
sion Science, Faculty of Medicine of Oporto. Rua Quinta do Sardoal, VE3,
nº10, 4430–182 V.N.Gaia, Portugal. Email: myworld_ana@hotmail.com
Copyright © 2014 John Wiley & Sons, Ltd.
pharmacoepidemiology and drug safety 2014; 23: 221–233
Published online 27 January 2014 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/pds.3566
be performed to clarify and assess what ophthalmic
ADRs can occur after the correct prescription of each
drug. A systematic review would be useful not only
to identify drugs in which ophthalmic ADRs are
frequent or serious, but also to increase knowledge of
physicians (prescribing physicians and ophthalmolo-
gists), enabling a greater detection of ophthalmic
ADRs after an ophthalmic examination and enabling
the construction of multi-disciplinary protocols when-
ever a high-risk drug is prescribed.
General ADRs are estimated to cause of 2.7% to
15.7% hospital admissions and to occur in 16.9% of
hospitalized patients (conﬁdence interval 95%:
13.6%, 20.2%).11 In a study performed in the United
States (US), it was estimated that more than 100 000
people die every year as a consequence of fatal ADRs,
placing fatal ADRs between the fourth and sixth lead-
ing causes of death in the US.12 However, the speciﬁc
frequency of ophthalmic ADRs is not known.
Although there are several studies about ophthalmic
ADRs, this theme presents with speciﬁc difﬁcul-
ties,13,14 and the methods of identiﬁcation and
reporting ADRs vary greatly.15,16 Some studies have
established recommendations,17,18 and others offer
guidelines to performing systematic reviews of studies
of ophthalmic ADRs.19,20
We intended to perform a general systematic review
about ophthalmic ADRs to systemic drugs in order to,
on the one hand, systematically summarize existing
evidence, and on the other hand, identify areas of spe-
ciﬁc ophthalmic ADRs or drugs that lacked systemati-
zation or assessment. This includes the identiﬁcation
of drugs that cause speciﬁc ophthalmic ADRs which
are well described in original studies but without
systematic review nor meta-analysis (therefore, oppor-
tunities for speciﬁc systematic reviews with meta-
analysis in the future are also identiﬁed).
METHODS
We performed a systematic review of studies that
assessed ophthalmic ADRs to systemic drugs according
to the guidelines of the Cochrane Collaboration19 and
PRISMA Statement,21 adapted to this theme.
Deﬁnitions
We used the following deﬁnition for adverse drug
reaction: “any noxious, unintended and undesired effect
of a drug, which occurs at doses used in humans for pro-
phylaxis, diagnosis, or therapy”, according to the World
Health Organization (WHO) deﬁnition22 of 1972.
An adverse event is: “an injury related to medical
management, in contrast to complications of
disease”.23 Medical management includes all aspects
of care, including diagnosis and treatment, failure to
diagnose or treat and the systems and equipment used
to deliver care.23 Therefore, to increase speciﬁcity, we
wanted to assess only adverse drug reactions.
Search methods
We searched through several electronic databases
(last date of search was 1/7/2012): Medline, SCOPUS,
ISI web of knowledge, ISI Conference Proceedings,
International Pharmaceutical Abstracts and Google
scholar. We used a search query created after a pilot
study to add speciﬁcity (full search query available if
requested to the corresponding author) that included
the terms: eye, ocular, ophthalmic, ophthalmology,
adverse and reaction. We searched for grey literature
and unpublished data and hand-searched all references
of included studies and relevant reviews.
Selection criteria
Studies were included if they followed all inclusion
criteria listed below:
(1) Studies in which the primary purpose was to assess
an ophthalmic ADR to a systemic medication.
Since there is a wide misuse of the terms ADR, ad-
verse event (AE) and adverse drug event (ADE), we
obtained also the full text of studies who claimed to
assess AEs or ADEs, to verify their methodology,
and to include the studies that actually assessed
ADRs, although they called it AEs or ADEs.
(2) Studies with patient evaluation performed by an
ophthalmologist.
(3) Studies that speciﬁed diagnostic criteria for an
ocular ADR.
We also included studies with different languages
(we hired a translator), any country and experimental
studies (if any). We did so to have a more thorough
and complete literature search. We did not exclude
systematic nor narrative reviews if they added useful
information about ocular ADRs, as we intended to
have a general overview that summarized and added
further systematization to existing evidence, and to
identify areas or speciﬁc ophthalmic ADRs that lacked
systematization or assessment.
Exclusion criteria:
(1) Studies assessing adverse events that did not
correspond to ADRs (for example, we excluded
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reports of capsular rupture in phacoemulsiﬁcation
surgery, but we did not exclude reports of capsular
rupture due to intra-operatory ﬂoppy iris syn-
drome, a syndrome that is an ADR provoked by
tamsulosine or other drugs).
(2) Systemic ADRs to topical ophthalmic drugs, or
ophthalmic ADRs to topical ophthalmic drugs
(they were not the purpose of our study and would
increase heterogeneity and reduce clarity of our
study).
(3) Studies that were comments or letters, if they
would not add new scientiﬁc evidence to our re-
view. However, letters or comments that included
case reports not published elsewhere about spe-
ciﬁc ocular ADRs were not excluded, in order to
identify rare ophthalmic ADRs.
(4) Studies assessing drugs already removed from the
market.
Data collection and extraction
Two independent reviewers, AM and FH, ﬁrst exam-
ined each title and abstract to exclude obviously irrel-
evant reports and then independently examined each
full text report, to determine eligibility according to in-
clusion criteria. Disagreements were solved by con-
sensus, recorded and analyzed using kappa statistics.
Primary outcome was the presence and type of ocu-
lar ADR and the respective causative systemic drug.
Secondary outcomes included: ocular structure af-
fected, diagnosis, serious or vision-threatening ADR.
All symptoms, visual acuity (VA), signals and results
of complementary examination performed at presenta-
tion were recorded, as well as after a follow-up. Atti-
tude or treatment performed for each ADR was also
registered (suspension of the causative drug, speciﬁc
treatment, administration of an antidote, no treatment
necessary). If VA was not recorded in the logMAR
scale,24 it was converted.
We always assessed the drug name, identiﬁed the
therapeutic drug class according to Anatomical Thera-
peutic Chemical Classiﬁcation System of WHO25 and
reported the number of days during which the drug
was used and the administration route (if that informa-
tion was available). We veriﬁed if causality was
assessed in the original studies (and according to what
classiﬁcation, preferably WHO’s23 or Naranjo’s,26 and
respective results) as well as predictability of ADRs
(using Hartwig’s predictability scale, for example),27
preventability (e.g. Schumok & Thornton’s preventabil-
ity criteria)28 and types of ADRs (Rawlins and
Thompson’s classiﬁcation29).We did not intend to iden-
tify all of the ophthalmic ADRs, but to systematize the
most important and the most frequent ADRs according
to the results of our systematic search.
Risk of bias assessment
We performed risk of bias assessment for each in-
cluded study and recorded it in a standardized form
created to assess ADR studies (in a previous work10)
and adapted to Ophthalmology after a pilot study.
We did not use scales (discouraged by the Cochrane
approach20) but criteria from Cochrane, STROBE,30
QUOROM31 and PRISMA21 adapted to the particular
scope of ophthalmic ADR evaluation, which included:
complete description of study design, description of
study type (case report, case series, prospective observa-
tional study, trial,…), adequate diagnostic criteria for
ophthalmic ADR, complete ophthalmologic evaluation
at presentation, quantiﬁed visual acuity at presentation
and follow-up, results of complementary testing
described at presentation and follow-up, deﬁnition of
ADR presented, rationale for study size, causality as-
sessment of ADR, preventability assessment of ADR,
description of all statistical methods, characterization
of study participants, description of methods to prevent
bias (information bias, selection bias and other bias) and
presentation of complete summary measures. The two
reviewers independently assessed study quality and risk
of bias; disagreements were solved by consensus.
Studies were divided in low risk of bias (5 or less
parameters with medium, unclear or high risk of bias),
medium risk (6 to 9) and high risk (10 or more parame-
ters evaluated as medium, unclear or high risk of bias).
RESULTS
Literature search
Pubmed search yielded 124 results; SCOPUS yielded
72 results; Google Scholar 60; ISI Web of Knowledge
yielded 154; others yielded 152. From these 562 stud-
ies (corresponding to 300 distinct studies), 163 were
selected to obtain full text and then 32 studies were
included9,17,32–61 (Fig. 1): 1 systematic review of
ADRs to a speciﬁc drug, 11 narrative reviews, 1 trial,
1 prospective study, 6 case–control or cohort or cross-
sectional studies, 6 spontaneous reports and 6 case
reports or case series. Kappa agreement for study in-
clusion was 0.80 during the ﬁrst phase and 0.82 during
the full text review (good agreement).
Characteristics of included studies
Table 1 summarizes the characteristics of included
studies. We identiﬁed several types of studies of ocular
ophthalmic adverse drug reactions — systematic review 223
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ADRs, most of them narrative reviews without sys-
tematic criteria nor bibliographic search.
Ophthalmic ADRs
Many different ophthalmic ADRs exist to many sys-
temic drugs. In Table 2, we represent a summary of
the main ophthalmic ADRs found in this systematic
review, according to each speciﬁc drug, dose, risk fac-
tors and tried to characterize the ophthalmic ADR (if
reported) and to evaluate the level of evidence of each
of the studies reporting each ADR (according to the
Oxford Levels of Evidence62). Keratitis, retinopathy,
glaucoma, dry eye and blurred vision were the most
frequent ADRs identiﬁed.
We identiﬁed many ophthalmic ADRs to drugs that
have original studies but are currently lacking a sys-
tematic review (therefore representing an opportunity
for further studies, as described in the Discussion
Section, below). Many studies were found but only
one systematic review (of ophthalmic ADRs to
sildenaﬁl56) and few narrative reviews with systematic
search were performed. Therefore, examples of drugs
that cause ophthalmic ADRs that would beneﬁt from
a recent and speciﬁc systematic review are: tamoxi-
fen, amiodarone, antidepressants, phenotiazines,
hydroxychloroquine, oral contraceptives, etc.
Risk of bias assessment
In Fig. 2, we present the summary of our quality eval-
uation of included studies, according to each parame-
ter assessed - risk of bias graph. Few studies had low
risk of bias. Only one study performed rationale for
study size. Most studies (25) performed a complete
initial evaluation by an ophthalmologist, but only 11
performed a follow-up of at least 1 month. Only 13
studies performed causality assessment for ADR and
only 7 applied or presented WHO’s deﬁnition of an
ADR. Risk of bias summary, which contains detailed
risk of bias assessment for each included study, is
available if requested to contact author.
DISCUSSION
What this study adds
There is an increasing number of studies of ophthalmic
ADRs. In spite of the common belief that ADRs in
Ophthalmology are rare, some ADRs might be ex-
tremely frequent (such as cornea verticillata caused
by amiodarone8), but require speciﬁc ophthalmologi-
cal examination for its detection. Every ocular struc-
ture might be affected by an ADR. There is a need
for performing speciﬁc systematic reviews of ophthal-
mic ADRs, because the majority of included studies
were narrative non-systematic reviews, most of which
without the strict application of WHO’s deﬁnition of
ADR nor causality assessment of ADRs.
Several drugs that may provoke different ophthal-
mic ADRs were identiﬁed, namely amiodarone,
sildenaﬁl, psychotropic drugs, alpha-blockers, cortico-
steroids and topiramate. Although cornea verticillata
is found very frequently in patients medicated with
amiodarone (authors report a rate of 100%46), this
ﬁnding rarely reduces visual function; on the other
hand, amiodarone may provoke a rare optic neuropa-
thy that may provoke marked visual loss.18 Sildenaﬁl
and tadalaﬁl have been recently studied, but while
some authors report no difference between ERG pat-
terns of placebo versus these drugs,53 others found
several ADRs associated with sildenaﬁl,58 namely:
ischemic optic neuropathy, central retinal vein occlu-
sion, cilio-retinal artery occlusion, acute angle closure
glaucoma and optic atrophy.
Strengths of our systematic review lie in the com-
prehensive search performed, the general increase in
systematization and characterization of ophthalmic
ADRs, the summary of existing evidence according
to WHO’s causality criteria for ADR and WHO’s def-
inition of ADR and ﬁnally the identiﬁcation of speciﬁc
ophthalmic ADRs that could beneﬁt from future spe-
ciﬁc systematic reviews with possible meta-analysis.
Limitations of our systematic review include not
only heterogeneity found in different types of ADRs
but also the extreme variability in the methodologies
of studies of ophthalmic ADRs (from isolated case re-
ports to retrospective series of spontaneous reports,
Figure 1. Flowchart of search strategy
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prospective observational studies and trials). These
limitations were expected, because this was a system-
atic review with a very general scope and because
the detection of ophthalmic ADRs depends on the de-
gree of suspicion and an adequately performed oph-
thalmologic examination. Many ophthalmic ADRs
are only detected by case reports or spontaneous re-
ports, representing a limitation but simultaneously an
opportunity to improve. Consequently, there are many
ophthalmic ADRs that are based on a low level of
evidence. We believe this is an additional reason for
applying systematically the WHO deﬁnition for
ADR and a causality assessment (whether WHO’s or
Naranjo’s), in order to decrease doubts. High-risk drugs
such as the ones identiﬁed in Table 2 should be associ-
ated with protocols of evaluation (especially in suscepti-
ble individuals or in high doses) by an ophthalmologist,
in order to detect sooner and with higher sensitivity and
speciﬁcity the respective ophthalmic ADRs.
CONCLUSION
Ophthalmologists’ education (to increase recognition of
ophthalmic ADRs) and the dissemination of protocols
of collaboration between Ophthalmology and other
Medicine specialties whenever they prescribe high-risk
drugs (such as sildenaﬁl, biphosphonates, psychiatric
medication, tamoxifen, hydroxichloroquine) are strong
suggestions for the future.
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KEY POINTS
• Ophthalmology is perhaps one of the medical
specialties in which there are the few assessed
ADRs, but the eye is a complex organ in which
minimal impairment can produce a substantial
functional effect.
• We performed a systematic review regarding oph-
thalmic ADRs to systemic drugs, to systematically
summarize evidence and to identify speciﬁc areas
that lacked systematization or assessment.
• From 562 studies initially found, only 32 were in-
cluded, and few studies had low risk of bias. Drugs
frequently involved included amiodarone, sildena-
ﬁl, hydroxychloroquine and biphosphonates.
• Many ophthalmic ADRs are frequent but remain
unnoticed; therefore, the systematization of spe-
ciﬁc ophthalmic ADRs, the increase of knowledge
and the dissemination of protocols of collaboration
are suggested.
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